logo-loader
RNS
Amryt Pharma PLC

Grant of Options

/**/ .j{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.j{}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 0cm}span.cy{color:black}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 10.0pt; text-align: center}span.cv{color:#00000A}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;text-align:justify;line-height: normal;background:white}table.de{margin-left:-10.8pt;border-collapse:collapse}td.cq{width:-.3pt;padding:0cm 5.4pt 0cm 5.4pt} p.df{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;text-align:justify;line-height: normal}span.cs{font-size:10.0pt;font-family:"Times New Roman","serif"; color:#00000A}td.cp{width:407.9pt;padding:0cm 5.4pt 0cm 5.4pt}table.dg{width:451.3pt;margin-left:-10.8pt;border-collapse:collapse}td.cm{width:142.65pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 10.0pt; text-align: center}td.cl{width:105.9pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ck{width:134.4pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ci{width:142.65pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.di{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;line-height:normal} td.cg{width:105.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 10.0pt; text-align: center}td.cf{width:134.4pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:10.0pt;line-height:normal;background: white}span.cd{font-family:"Arial","sans-serif";color:#00000A}p.dl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 10.0pt}p.dm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify;line-height: normal;background:white}td.bx{width:38.45pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 6.0pt; margin-left: 35.45pt; margin-right: 0cm; margin-top: 6.0pt; text-align: justify; text-indent: -35.45pt}span.bz{text-transform:uppercase} td.bv{width:377.05pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt; text-align: justify}td.bt{width:38.45pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify;line-height:normal}td.bs{width:123.75pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.br{width:242.45pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bq{width:377.05pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bp{width:123.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;line-height:normal}p.dr{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt} td.bm{width:38.4pt;border-top:none;border-left:solid windowtext 1.0pt; border-bottom:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bl{width:123.75pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bk{width:242.45pt;border:none; border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.bj{width:38.4pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}tr.bc{height:8.95pt}td.bi{width:38.45pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.bh{width:123.75pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.bg{width:-7.5pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.bf{width:86.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.be{width:89.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt} td.bd{width:-9.7pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}tr.ax{height:8.9pt}td.bb{width:-7.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}td.ba{width:86.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}td.az{width:89.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}td.ay{width:-9.7pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}p.ds{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:18.0pt;text-align:justify;text-indent:-18.0pt;line-height: normal}span.aw{font-family:Symbol}p.dt{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;background:white}p.du{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt; text-align: justify} span.at{color:black;text-transform:uppercase}td.ar{width:38.45pt;border-top:none;border-left: solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aq{width:123.8pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.ap{font-size:10.0pt;font-family:"Times New Roman","serif"; color:black}td.ao{width:123.8pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.an{width:86.65pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.am{width:-9.6pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.95pt}td.al{width:86.65pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}td.ak{width:-9.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:8.9pt}span.aj{font-family:Symbol;color:black} p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.dv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;text-align:justify}table.dw{width:448.25pt;margin-left:-7.1pt;border-collapse:collapse}tr.ad{height:15.0pt}td.ag{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}p.dx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%}td.ae{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}p.dy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height:115%}p.dz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:115%}span.ac{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"} span.aa{font-size:5.0pt; line-height:115%}p.ea{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: 115%}p.eb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic}tr.v{height:16.35pt}td.x{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt}td.w{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt}tr.s{height:4.05pt}td.u{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.05pt}td.t{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.05pt}p.ec{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: 12.65pt; margin-bottom: 0cm} p.ed{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.ee{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ef{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.eg{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.eh{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.l{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.ei{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.m{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.p{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.ej{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify} /**/
RNS Number : 9132Z
Amryt Pharma PLC
22 May 2019
 

22 May 2019

AIM: AMYT

Euronext Growth: AYP

 

Amryt Pharma plc

("Amryt" or the "Company")

 

Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities

Amryt announces that the Remuneration Committee has approved the grant of 3,407,734 share options ("Options") to subscribe for ordinary shares of 1p each in the Company ("Shares") under the Employee Share Option Plan 2016 (the "Plan") to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.

The Options have an exercise price of 12.64p ("Exercise Price"). These options may be exercised as follows:

25% of the total Options granted may be exercised 12 months after the date of grant;

a further 25% of the total Options granted may be exercised 24 months after the date of grant; and

the balance of the Options may be exercised 36 months after the date of grant.

 

All Options are subject to change of control provisions and expire on the seventh anniversary of their grant.

Following the grants of these options, the following Directors have the following options:

Director

Options granted

Total Options now held

Joe Wiley

1,896,239

3,957,369

Rory Nealon

1,511,495

2,335,947

 

PDMR Dealings

The notification of dealing forms for each Director can be found below.  This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

1.           

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Joe Wiley

2.

Reason for the notification

a)

Position / status

Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800BOS8WAJO2BEQ38

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

 

 

Identification code

ISIN: GB00BDD1LS57

b)

Nature of the transaction

Grant of options under the Employee Share Option Plan 2016 with an exercise price of 12.64p to purchase 1,896,239 ordinary shares. 

c)

Currency

British Pounds

d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

N/A

1,896,239

 

e)

Aggregated information

· Aggregated volume

· Aggregated price

 

1,896,239

N/A

f)

Date of the transaction

21 May 2019

g)

Place of the transaction

Outside a trading venue

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Rory Nealon

2.

Reason for the notification

a)

Position / status

Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800BOS8WAJO2BEQ38

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

 

 

Identification code

ISIN: GB00BDD1LS57

b)

Nature of the transaction

Grant of options under the Employee Share Option Plan 2016 with an exercise price of 12.64p to purchase 1,511,495 ordinary shares. 

c)

Currency

British Pounds

d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

N/A

1,511,495

 

e)

Aggregated information

·Aggregated volume

·Aggregated price

 

1,511,495

N/A

f)

Date of the transaction

21 May 2019

g)

Place of the transaction

Outside a trading venue

 

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

 

 

Shore Capital

+44 (0) 20 7408 4090

Financial Advisor, NOMAD and Joint Broker

 

Edward Mansfield, Mark Percy, Daniel Bush

 

 

Stifel

+44 (0) 20 7710 7600

Joint Broker

 

Jonathan Senior, Ben Maddison

 

 

Davy

+353 (1) 679 6363

Euronext Growth Advisor and Joint Broker

 

John Frain, Daragh O'Reilly

 

 

Consilium Strategic Communications

+44 (0) 20 3709 5700

Amber Fennell, Matthew Neal, David Daley
 

 

 

About Amryt

 

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.  

 

Lojuxta® is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels.  Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

 

Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta® (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

 

Amryt's lead development candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment.  It is currently in Phase 3 clinical trials and recently reported positive unblinded interim efficacy analysis results and is anticipated will be fully enrolled by end of H2 2019. The European and US market opportunity for EB is estimated to be in excess of $1 billion.

 

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. 

 

In May 2019, Amryt announced the planned acquisition of Aegerion Pharmaceuticals. This Transaction will put Amryt on the path to creating a rare and orphan disease company with a diversified offering of multiple commercial and development stage assets and will provide it with scale to support further growth. The Transaction will give Amryt an expanded commercial footprint to market two US and EU approved products, lomitapide (Juxtapid® (US/ROW) / Lojuxta® (EU)) and metreleptin (Myalept® (US) / Myalepta® (EU)). Amryt's leadership team already has a deep knowledge of both these products and since December 2016 has successfully commercialized Lojuxta® across Europe and the Middle East.

 

 

For more information on Amryt, please visit www.amrytpharma.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHSEAFWEFUSEFI

Quick facts: Amryt Pharma PLC

Price: £1.29

Market: AIM
Market Cap: £64.99 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

RNS

Circular to Shareholders

3 days, 23 hours ago

Update on Acquisition of Aegerion

5 days, 15 hours ago

Schedule One

1 week, 5 days ago

Schedule One - Amryt Pharma plc

1 week, 5 days ago

Holdings in Company

2 weeks ago

Holding(s) in Company

2 weeks, 4 days ago